InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in ChinaInnoCare has introduced their second ADC, ICP-B208, from their proprietary platform into clinical development. Currently, there are no ADCs targeting CDH17 that have been approved worldwide.
